Novo Nordisk A/S

Novo Nordisk agreed to pay USD 58.65 million in 2017 to resolve U.S. allegations that its U.S. subsidiary failed to comply with an FDA-mandated Risk Evaluation and Mitigation Strategy for the diabetes drug Victoza and related False Claims Act allegations. The resolution included USD 12.15 million in disgorgement tied to alleged FDCA violations from 2010 to 2012 and USD 46.5 million relating to alleged False Claims Act violations from 2010 to 2014. Source: https://www.justice.gov/archives/opa/pr/novo-nordisk-agrees-pay-58-million-failure-comply-fda-mandated-risk-program